The performance of companies tied to blockbuster drugs like Viagra presents a challenging investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key markets has introduced considerable risk . Investors are now assessing the effect of generic co